By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street, Suite 103

Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics, Inc. Appoints Benjamin Rivnay, Ph.D. To Chief Scientist 7/9/2014 11:28:56 AM
Boston Therapeutics, Inc. Initiates Phase 2b Study To Assess The Efficacy And Safety Of SUGARDOWN® For Type 2 Diabetes 5/29/2014 10:18:01 AM
Boston Therapeutics, Inc. To Present At SeeThruEquity Microcap Investor Conference On May 28 And Marcum Microcap Conference On May 29 5/28/2014 11:11:47 AM
Boston Therapeutics, Inc. Announces Strategic Marketing Agreement With Benchworks SD Aimed At Growing Sales Of SUGARDOWN® 5/20/2014 9:35:02 AM
Boston Therapeutics, Inc. Reports Corporate Update and Financial Results For The First Quarter Ended March 31, 2014 5/14/2014 9:39:02 AM
Boston Therapeutics, Inc. Signs Agreement With Patheon To Manufacture Pharmaceutical-Grade BTI-320 Tablets 5/6/2014 9:36:13 AM
Boston Therapeutics, Inc. To Present Late-Breaking Poster On Mechanism Of Action For BTI-320 At American Association of Clinical Endocrinologists Annual Congress In Las Vegas On May 14-18 4/29/2014 11:13:38 AM
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) On Boston Therapeutics, Inc. 3/28/2014 8:29:20 AM
Boston Therapeutics, Inc. Research Update Released 3/26/2014 11:36:12 AM
SeeThruEquity Issues Quarterly Update On Boston Therapeutics, Inc. 3/18/2014 9:35:47 AM